- Email: [email protected]
P-42 Patterns of oral antihyperglycemic therapy and level of glycemic control among patients with Type 2 diabetes mellitus (T2DM) in Taiwan
S70
DIABETES RESEARCH A N D CLINICAL PRACTICE
P-41 Level of glycemic control and patterns of oral antihyperglycemic therapy among patients with Type 2 diabetes mellitus (T2DM) in Thailand Wannee Nitiyanant, Pongamorn Bunnag, Sompongse Suwanwalaikorn, Yupin Benjasuratwong. for the Thai RECAP Study Group Department of Medicine, Siriraj Hospital, Bangkok, Thailand Objectives: To assess patterns of oral anti-hyperglycemic therapy and level of glycemic control among patients with T2DM treated with oral anti-hyperglycemic agents (OHA). Methods: A retrospective clinical chart review and blood tests at the time of visit (Jan-Sep 2007) were conducted in Thailand. Patients were ≥ 30 years at the time of T2DM diagnosis and had been taking OHA (mono/combination therapy) for at least 6 months. Patients with gestational diabetes or treated with insulin in the last year were excluded. All patients gave informed consent. Information on demographics, diabetes history, concomitant medications and co-morbid conditions was extracted from clinical charts up to 6 months prior to the enrollment date. The proportion of patients at HbA1c goals of <7% and <6.5% was assessed. Results: A total of 338 patients were recruited in this study. Average age was 60 (SD=11) years, 38% were male, and mean duration of T2DM was 8.6 years. The mean HbA1C was 8.0% (SD=1.5), 20% (69 patients) and 9% (30 patients) were at HbA1C goal of < 7% and <6.5% respectively. Based on the recorded treatments during the 3 months prior to the HbA1C test, the distribution of OHA received by these patients is included in the following table (treatment information is missing for 1 patient):
N (%) HbA1c, mean (SD) HbA1c < 7%, n (%) HbA1c < 6.5%, n (%)
SU alone
Met alone
Other mono
Met+SU
Other comb
All
33 (9.8) 8.0 (1.6) 5 (15) 2 (6)
62 (18.4) 7.5 (1.2) 17 (27) 7 (11)
2 (0.6) 7.1 (0.2) –
154 (45.7) 8.2 (1.6) 32 (21) 12 (8)
86 (25.5) 8.1 (1.3) 14 (16) 8 (9)
338
–
8.0 (1.5) 69 (20) 30 (9)
Conclusions: In this cohort of Thai patients with T2DM receiving OHA, about 71% of patients were on a combination of metformin with a SU or other combinations. Only about onefifth and one- tenth of the patients were at the HbA1c goals of <7% and <6.5% respectively.
P-42 Patterns of oral antihyperglycemic therapy and level of glycemic control among patients with Type 2 diabetes mellitus (T2DM) in Taiwan Wayne Huey-Herng Sheu Taichung Veterans General Hospital, Taichung, Taiwan Objectives: To assess patterns of oral anti-hyperglycemic therapy and level of glycemic control among patients with T2DM treated with oral anti-hyperglycemic agents (OHA). Methods: A retrospective clinical chart review and blood test at the time of visit (Jan-Jun 2007) were conducted in Taiwan. Patients were ≥ 30 years at the time of T2DM diagnosis and had been taking OHA (mono/combination therapy) for at least 6 months. Patients with gestational diabetes or treated with insulin in the last year were excluded. All patients gave informed consent. Information on demographics, diabetes history, con-
79 (2008) S1 – S127
comitant medications and co-morbid conditions was extracted from clinical charts up to 6 months prior to the enrollment date. Glycemic goal was defined according to the IDF (2005) recommendations as HbA1C<6.5%. Results: A total of 609 patients were included in this analysis. Average age was 58 (SD=11) years, 54% were male, and mean duration of diabetes was 7.6 years. The mean A1C was 7.7% (SD=1.4) and 15% (90 patients) were at HbA1C goal. Based on the recorded treatments during the 3 months prior to the HbA1C test measurement, the distribution of OHA received by these patients is included in Table 1. Table 1 SU Met AGI Other Met+SU Other All alone alone alone mono comb % (N)
8.1 (49) A1c, mean (SD) 7.2 (1.1) A1c<6.5% (proportion) 22
12.6 (77) 7.1 (1.1) 25
1.0 (6) 6.9 (0.3) 17
2.8 (17) 6.7 (1.1) 47
36.6 (223) 7.8 (1.4) 11
38.9 100 (237) (609) 8.0 7.7 (1.5) (1.4) 11 15
Conclusions: In this cohort of T2DM patients receiving OHA in Taiwan, about 76% of patients received a combination of metformin with a SU or other combinations. Only about 15% of the patients were at the IDF recommended HbA1C goal.
P-43 Patterns of oral antihyperglycemic therapy and status level of glycemic control among patients with Type 2 diabetes mellitus (T2DM) managed at general hospitals in Korea Sei Hyun Baik. on behalf of RECAP* Korea Investigators’ Group Korea University Guro Hospital, Seoul, Korea Background: It is well known that the majority of T2DM patients do not reach treatment targets. We need to understand the treatment pattern of diabetes specialists with oral hypoglycemic agents for insulin naive T2DM patients. Target patients were T2 DM patients under treatment of an Endocrinologist at a general hospital. Patients were well-educated and currently on oral antihyperglycemic agents who were naive to insulin therapy. Objectives: To assess patterns of oral hypoglycemic agent therapy and status of glycemic control among patients who are treated by diabetes specialists in general hospitals in Korea Methods: Blood for fasting glucose, insulin and HbA1c (A1C), patient surveys, and medical record review at a routine visit between January and June 2007 were conducted in 13 general hospitals in Korea. Patients managed by hospital based endocrinologists who were ≥ 30 years at the time of T2DM diagnosis and had been taking OHA (mono/combination therapy) for at least 6 months. Patients with gestational diabetes or treated with insulin in the last year were excluded. All patients gave informed consent. Information on demographics, diabetes history, concomitant medications and co-morbid conditions was extracted from clinical charts up to 6 months prior to the enrollment date. Glycemic goal was defined according to the IDF (2005) recommendations as A1C<6.5%. Results: A total of 295 patients were included in this analysis. Average age was 58 (SD=9.3) years, 46% were male, and mean
SU Met AGI Other Met+SU Other ALL alone alone alone mono U comb %
13.2 (N) (39) A1c, mean 6.9 (SD) (1.0) A1c < 6.5% (proportion) 36
6.8 (20) 7.1 (1.3) 45
1.0 (3) – –
5.4 (16) 6.3 (0.6) 56
32.9 (97) 7.2 (1.1) 21
39.7 100 (117) (295) 7.0 7.0 (1.0) (1.0) 37 33
DIABETES RESEARCH A N D CLINICAL PRACTICE
P-41 Level of glycemic control and patterns of oral antihyperglycemic therapy among patients with Type 2 diabetes mellitus (T2DM) in Thailand Wannee Nitiyanant, Pongamorn Bunnag, Sompongse Suwanwalaikorn, Yupin Benjasuratwong. for the Thai RECAP Study Group Department of Medicine, Siriraj Hospital, Bangkok, Thailand Objectives: To assess patterns of oral anti-hyperglycemic therapy and level of glycemic control among patients with T2DM treated with oral anti-hyperglycemic agents (OHA). Methods: A retrospective clinical chart review and blood tests at the time of visit (Jan-Sep 2007) were conducted in Thailand. Patients were ≥ 30 years at the time of T2DM diagnosis and had been taking OHA (mono/combination therapy) for at least 6 months. Patients with gestational diabetes or treated with insulin in the last year were excluded. All patients gave informed consent. Information on demographics, diabetes history, concomitant medications and co-morbid conditions was extracted from clinical charts up to 6 months prior to the enrollment date. The proportion of patients at HbA1c goals of <7% and <6.5% was assessed. Results: A total of 338 patients were recruited in this study. Average age was 60 (SD=11) years, 38% were male, and mean duration of T2DM was 8.6 years. The mean HbA1C was 8.0% (SD=1.5), 20% (69 patients) and 9% (30 patients) were at HbA1C goal of < 7% and <6.5% respectively. Based on the recorded treatments during the 3 months prior to the HbA1C test, the distribution of OHA received by these patients is included in the following table (treatment information is missing for 1 patient):
N (%) HbA1c, mean (SD) HbA1c < 7%, n (%) HbA1c < 6.5%, n (%)
SU alone
Met alone
Other mono
Met+SU
Other comb
All
33 (9.8) 8.0 (1.6) 5 (15) 2 (6)
62 (18.4) 7.5 (1.2) 17 (27) 7 (11)
2 (0.6) 7.1 (0.2) –
154 (45.7) 8.2 (1.6) 32 (21) 12 (8)
86 (25.5) 8.1 (1.3) 14 (16) 8 (9)
338
–
8.0 (1.5) 69 (20) 30 (9)
Conclusions: In this cohort of Thai patients with T2DM receiving OHA, about 71% of patients were on a combination of metformin with a SU or other combinations. Only about onefifth and one- tenth of the patients were at the HbA1c goals of <7% and <6.5% respectively.
P-42 Patterns of oral antihyperglycemic therapy and level of glycemic control among patients with Type 2 diabetes mellitus (T2DM) in Taiwan Wayne Huey-Herng Sheu Taichung Veterans General Hospital, Taichung, Taiwan Objectives: To assess patterns of oral anti-hyperglycemic therapy and level of glycemic control among patients with T2DM treated with oral anti-hyperglycemic agents (OHA). Methods: A retrospective clinical chart review and blood test at the time of visit (Jan-Jun 2007) were conducted in Taiwan. Patients were ≥ 30 years at the time of T2DM diagnosis and had been taking OHA (mono/combination therapy) for at least 6 months. Patients with gestational diabetes or treated with insulin in the last year were excluded. All patients gave informed consent. Information on demographics, diabetes history, con-
79 (2008) S1 – S127
comitant medications and co-morbid conditions was extracted from clinical charts up to 6 months prior to the enrollment date. Glycemic goal was defined according to the IDF (2005) recommendations as HbA1C<6.5%. Results: A total of 609 patients were included in this analysis. Average age was 58 (SD=11) years, 54% were male, and mean duration of diabetes was 7.6 years. The mean A1C was 7.7% (SD=1.4) and 15% (90 patients) were at HbA1C goal. Based on the recorded treatments during the 3 months prior to the HbA1C test measurement, the distribution of OHA received by these patients is included in Table 1. Table 1 SU Met AGI Other Met+SU Other All alone alone alone mono comb % (N)
8.1 (49) A1c, mean (SD) 7.2 (1.1) A1c<6.5% (proportion) 22
12.6 (77) 7.1 (1.1) 25
1.0 (6) 6.9 (0.3) 17
2.8 (17) 6.7 (1.1) 47
36.6 (223) 7.8 (1.4) 11
38.9 100 (237) (609) 8.0 7.7 (1.5) (1.4) 11 15
Conclusions: In this cohort of T2DM patients receiving OHA in Taiwan, about 76% of patients received a combination of metformin with a SU or other combinations. Only about 15% of the patients were at the IDF recommended HbA1C goal.
P-43 Patterns of oral antihyperglycemic therapy and status level of glycemic control among patients with Type 2 diabetes mellitus (T2DM) managed at general hospitals in Korea Sei Hyun Baik. on behalf of RECAP* Korea Investigators’ Group Korea University Guro Hospital, Seoul, Korea Background: It is well known that the majority of T2DM patients do not reach treatment targets. We need to understand the treatment pattern of diabetes specialists with oral hypoglycemic agents for insulin naive T2DM patients. Target patients were T2 DM patients under treatment of an Endocrinologist at a general hospital. Patients were well-educated and currently on oral antihyperglycemic agents who were naive to insulin therapy. Objectives: To assess patterns of oral hypoglycemic agent therapy and status of glycemic control among patients who are treated by diabetes specialists in general hospitals in Korea Methods: Blood for fasting glucose, insulin and HbA1c (A1C), patient surveys, and medical record review at a routine visit between January and June 2007 were conducted in 13 general hospitals in Korea. Patients managed by hospital based endocrinologists who were ≥ 30 years at the time of T2DM diagnosis and had been taking OHA (mono/combination therapy) for at least 6 months. Patients with gestational diabetes or treated with insulin in the last year were excluded. All patients gave informed consent. Information on demographics, diabetes history, concomitant medications and co-morbid conditions was extracted from clinical charts up to 6 months prior to the enrollment date. Glycemic goal was defined according to the IDF (2005) recommendations as A1C<6.5%. Results: A total of 295 patients were included in this analysis. Average age was 58 (SD=9.3) years, 46% were male, and mean
SU Met AGI Other Met+SU Other ALL alone alone alone mono U comb %
13.2 (N) (39) A1c, mean 6.9 (SD) (1.0) A1c < 6.5% (proportion) 36
6.8 (20) 7.1 (1.3) 45
1.0 (3) – –
5.4 (16) 6.3 (0.6) 56
32.9 (97) 7.2 (1.1) 21
39.7 100 (117) (295) 7.0 7.0 (1.0) (1.0) 37 33